Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium
Pompe Disease, also known as glycogenosis type 2, is due to deficiency in lysosomal alpha- glucosidase, a lysosomal hydrolase, which presents infantile and late onset subtypes (LOPD). The myopathy in LOPD can be reversed by Enzyme Replacement Therapy (ERT), but might benefit from a concomitant low c...
Saved in:
Main Author: | Corrado Angelini (Author) |
---|---|
Format: | Book |
Published: |
PAGEPress Publications,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cognitive Outcome of Infants with Pompe Disease Receiving Enzyme-Replacement Therapy
by: J Gordon Millichap
Published: (2012) -
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
by: Lina Fiege, et al.
Published: (2023) -
Considerations for evaluating the effectiveness and long-term outcome of enzyme replacement therapy in Pompe disease
by: Chong Kun Cheon
Published: (2020) -
Effect of the enzyme replacement therapy on hypertrophic cardiomyopathy in an infant with the CRIM-negative infantile Pompe's disease
by: Guy Vaksmann, et al.
Published: (2021) -
Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis
by: A. D. Dornelles, et al.
Published: (2024)